TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/04/2024
Voltar para busca
Dado oficial do USPTO
SHORLA PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SHORLA PHARMA
ST13
US500000088861759Classe
5, 42
Pedido
88861759
Registro
6533302
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
23
Atualização mais recente
25/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
06/04/2020
Data de registro
26/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/10/2021
Última transação
25/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Clonmel, Co. Tipperary, IE
Examinador
MARTIN, CHRISTINE C
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Shorla Pharma Limited
Representantes
Sean P. McMahon SEAN P. MCMAHON, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical and medicinal preparations and substances for the treatment of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; pharmaceutical and medicinal preparations and substances for use in oncology; pharmaceutical preparations and substances for human use for the treatment of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; pharmaceutical preparations and substances for the prevention and treatment of cancer; pharmaceutical compounds for treating cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of tumors; anti-cancer drugs and pharmaceutical preparations
Classe 42
research and development services in the field of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; biological research; scientific research services; research and development services in the pharmaceutical and biotechnology fields; research services relating to the development and testing of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical product evaluation; testing and inspection of pharmaceutical preparations and medicines; conducting clinical trials for pharmaceutical products; product safety and quality testing in the pharmaceutical and biotechnology fields; provision of information and data relating to research and development in the pharmaceutical and biotechnology fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
23 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/04/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
26/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/08/2021
PUBO
PUBLISHED FOR OPPOSITION
10/08/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/06/2021
ALIE
ASSIGNED TO LIE
07/06/2021
NREV
NOTICE OF REVIVAL - E-MAILED
12/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/03/2021
PETG
PETITION TO REVIVE-GRANTED
11/03/2021
PROA
TEAS PETITION TO REVIVE RECEIVED
11/03/2021
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
11/01/2021
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
11/01/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/06/2020
GNRT
NON-FINAL ACTION E-MAILED
29/06/2020
CNRT
NON-FINAL ACTION WRITTEN
29/06/2020
DOCK
ASSIGNED TO EXAMINER
24/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/04/2020
NWAP
NEW APPLICATION ENTERED
09/04/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SHORLA PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.